Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Spiessens

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Biometrics|December 23, 2015
A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studiesJunlong Li, Lihui Zhao, Lu Tian, et al.
Open Forum Infectious Diseases|August 23, 2023
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a StudyCarlos A Fierro, Michal Sarnecki, Joachim Doua, et al.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|May 29, 2007
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvantCourt Pedersen, Tiina Petaja, Gitte Strauss, et al.
NPJ Vaccines|June 14, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTICarlos A Fierro, Michal Sarnecki, Bart Spiessens, et al.
Epidemiology and Infection|January 6, 2025
Epidemiology of invasive <i>Escherichia coli</i> disease in adults in England, 2013-2017Maxim Blum, Jeroen Geurtsen, Eva Herweijer, et al.
The Lancet. Infectious Diseases|May 14, 2019
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trialRobert W Frenck, John Ervin, Laurence Chu, et al.
The Journal of Urology|January 6, 2021
Reply by AuthorsSteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
The Journal of Urology|October 20, 2020
Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter StudySteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapyFernando Ulloa-Montoya, Jamila Louahed, Benjamin Dizier, et al.
Vaccines|February 26, 2026
Immunogenicity and Safety of the ExPEC9V <i>Escherichia coli</i> Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 StudyIsabel Leroux-Roels, Tracey A Day, Sofie Deleu, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Biometrics|December 23, 2015
A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studiesJunlong Li, Lihui Zhao, Lu Tian, et al.
Open Forum Infectious Diseases|August 23, 2023
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a StudyCarlos A Fierro, Michal Sarnecki, Joachim Doua, et al.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|May 29, 2007
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvantCourt Pedersen, Tiina Petaja, Gitte Strauss, et al.
NPJ Vaccines|June 14, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTICarlos A Fierro, Michal Sarnecki, Bart Spiessens, et al.
Epidemiology and Infection|January 6, 2025
Epidemiology of invasive <i>Escherichia coli</i> disease in adults in England, 2013-2017Maxim Blum, Jeroen Geurtsen, Eva Herweijer, et al.
The Lancet. Infectious Diseases|May 14, 2019
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trialRobert W Frenck, John Ervin, Laurence Chu, et al.
The Journal of Urology|January 6, 2021
Reply by AuthorsSteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
The Journal of Urology|October 20, 2020
Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter StudySteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapyFernando Ulloa-Montoya, Jamila Louahed, Benjamin Dizier, et al.
Vaccines|February 26, 2026
Immunogenicity and Safety of the ExPEC9V <i>Escherichia coli</i> Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 StudyIsabel Leroux-Roels, Tracey A Day, Sofie Deleu, et al.
Pageof 4